Arcus Biosciences, Inc. completed a substantial public offering of Common Stock on November 3, 2025, following an Underwriting Agreement dated October 30, 2025. The offering involved the sale of 15,755,000 shares at a price of \(18.25 per share, raising approximately \)269.7 million in net proceeds. This financing, documented under Form S-3, bolsters the company’s balance sheet. Underwriters were led by Leerink Partners and Goldman Sachs.
Key transaction terms include a 60-day lock-up period effective November 3, 2025, for officers, directors, and major stockholders, including Gilead Sciences,
...